查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1985814

Biperiden市场：2026-2032年全球市场预测（依剂型、类型、适应症、给药途径、患者年龄层及最终用户划分）

Biperiden Market by Formulation, Type, Indication, Route Of Administration, Patient Age Group, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，Biperiden市场价值将达到 4.071 亿美元，到 2026 年将成长至 4.3397 亿美元，到 2032 年将达到 6.3693 亿美元，复合年增长率为 6.60%。

主要市场统计数据
基准年 2025 4.071亿美元
预计年份：2026年 4.3397亿美元
预测年份 2032 6.3693亿美元
复合年增长率 (%) 6.60%

全面介绍比Biperiden的药理特性、临床效用、安全性以及在治疗运动障碍的持续作用。

Biperiden是一种抗胆碱能药物，在运动障碍的症状治疗中发挥重要作用，尤其适用于帕金森氏症症状和药物引起的锥体外系反应。临床医生持续利用其药理特性来调节毒蕈碱受体介导的信号通路，从而减轻特定患者群体的震颤和僵硬症状。根据给药途径的不同，比哌立登的製剂和剂量也会有所变化，这使得临床医生能够在治疗目标和耐受性之间取得平衡，尤其适用于通常合併多种药物和多种其他疾病的老年患者。

分析推动比Biperiden治疗和商业性领域策略和营运变革的临床、监管和供应链因素。

Biperiden的治疗和商业性格局正经历着许多变革，其驱动因素包括不断演变的临床指南、人口结构变化以及供应链趋势。临床上，人们越来越重视个人化治疗，充分考虑与老龄化相关的动态以及多重用药导致的抗胆碱能作用的累积负担。这一趋势促使医生更加谨慎地开立处方并加强监测，进而影响着医疗机构中不同剂型和需求模式的变化。

评估政策主导的关税调整如何改变了Biperiden供应链的经济、采购行为和连续性计画。

美国于2025年实施的关税政策变化所带来的累积影响，进一步加剧了医药原料和成品采购及分销环节的复杂性。部分进口医药原料和包装材料关税的提高，加剧了依赖全球供应链的製造相关人员的原料成本压力。这些压力透过契约製造製造商和批发商传递至医疗机构等采购方，迫使他们调整筹资策略和库存计画。

我们根据细分市场的具体情况，制定临床和商业策略，整合製剂、类型、适应症、给药途径、患者人口统计特征和最终用户特征。

从市场区隔观点获得的洞察揭示了不同的临床和商业性趋势，这些趋势有助于产品定位和相关人员。按剂型划分，市场分为注射剂和口服剂型，其中口服剂型在2毫克和4毫克的既定剂量水平下进行了进一步评估。注射剂型在医疗机构的急性期治疗中仍发挥重要作用，而口服剂型则可用于剂量调整和门诊维持治疗。按剂型划分，品牌药与学名药往往强调剂型和供应可靠性，而学名药优先考虑处方笺广泛性和成本控制。以适应症划分，产品主要用于治疗锥体外系症状和帕金森氏症，每种适应症的处方模式、监测要求和患者疗效预期均有所不同。

对美洲、欧洲、中东和非洲以及亚太地区比Biperiden的取得途径进行监管、采购、製造和临床引入趋势的区域分析。

区域趋势影响全球Biperiden的需求驱动因素、监管互动和供应链优先事项。在美洲，强调处方集效率和成本控制的政策指导支付方的谈判策略，而一体化的分销网络促进了业务的快速扩张，同时对影响进口原材料的关税和贸易政策的变化保持敏感。在欧洲、中东和非洲，不同的法规结构和区域医疗基础设施差异导致了不同的部署路径。一些地区优先考虑集中采购和严格的药物安全监测，而其他地区则优先考虑与当地製造伙伴关係建立合作关係以确保供应的连续性。在亚太地区，生产能力、活性成分采购以及对老年护理日益增长的关注是决定治疗优先事项的关键因素，区域生产基地在全球供应链中发挥核心作用。

决定比Biperiden产品供应、配方差异化和临床支援的製造商、合约合作伙伴和服务供应商的竞争和业务趋势资讯。

製造商、合约开发商和专业供应商之间的竞争正在影响Biperiden的供应、製剂创新和供应可靠性。成熟的学名药生产商透过大规模生产和分销网络维持着广泛的供应，而专业製药公司则透过改进製剂、提高注射剂稳定性或定製包装以提高给药精度来脱颖而出。随着委託公司将生产外包以控制资本密集度和满足监管合规要求，合约开发和生产组织 (CDMO) 的重要性日益凸显。因此，健全的品管系统和多元化的供应商基础是至关重要的竞争优势。

为製造商、经销商和医疗保健相关人员提供切实可行的策略和营运建议，以确保获得Biperiden并优化其使用。

产业领导企业应采取多管齐下的策略，在控製成本和监管风险的同时，保障患者取得所需药物。首先，透过原料药原料药多元化认证多家契约製造伙伴，增强供应链韧性，可以降低贸易政策波动和产能瓶颈带来的风险。其次，投资製剂的稳健性－提高注射剂的稳定性，优化临床适用口服製剂的均一性－可以解决临床医师对药物可靠性和依从性的担忧。第三，加强上市后安全性监测和临床医生教育项目，特别关注老年患者的抗胆碱能药物负担，将有助于降低安全风险，并支持合理的处方实践。

透过结合文献整合、相关人员访谈和供应链映射的严谨、多方面的调查方法，我们获得了基于临床、具有实际意义的见解。

本分析的调查方法结合了系统性文献回顾、监管指南整合、相关人员访谈和供应链图谱分析，以确保全面的证据基础。二手资料，包括同行评审的临床文献、药理学参考文献和公开的监管文件，用于确定临床背景和安全性考虑。主要研究包括对临床医生、采购负责人和生产专家进行结构化访谈，以了解实际的处方模式、采购重点和营运限制。这些发现检验，以检验主题并协调不同医疗机构的观点。

总结了在医疗保健机构中维持比Biperiden的可近性和安全使用的临床意义、营运挑战和策略重点。

总之，Biperiden在治疗运动障碍方面仍具有临床价值，尤其适用于某些帕金森氏症相关症状和药物引起的锥体外系反应。临床偏好、监管预期、人口趋势和供应链压力相互作用，正在重塑相关人员选择药物、采购和病人安全管理的方式。适应这些趋势需要生产、临床实践和采购部门通力合作，以确保药物供应符合不断发展的医疗保健标准。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：Biperiden市场以剂型划分

  • 注射药物
  • 口服
    • 2 mg
    • 4 mg

第九章：Biperiden市场：按类型划分

  • 品牌商品
  • 非专利的

第十章：Biperiden市场：依适应症划分

  • 锥体外系症状
  • 帕金森氏症

第十一章：Biperiden市场：依给药途径

  • 口服
  • 肠外

第十二章 依病患年龄层Biperiden市场

  • 成人
  • 老年人

第十三章：Biperiden市场：依最终用户划分

  • 诊所
  • 居家照护
  • 医院

第十四章Biperiden市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章：比Biperiden市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章Biperiden市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国Biperiden市场

第十八章：中国Biperiden市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Apotex Inc.
  • Aurobindo Pharma Limited
  • Dr. Reddy's Laboratories Ltd.
  • Glenmark Pharmaceuticals Limited
  • Janssen-Cilag International NV
  • Lupin Limited
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-351BAD503D4E

The Biperiden Market was valued at USD 407.10 million in 2025 and is projected to grow to USD 433.97 million in 2026, with a CAGR of 6.60%, reaching USD 636.93 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 407.10 million
Estimated Year [2026] USD 433.97 million
Forecast Year [2032] USD 636.93 million
CAGR (%) 6.60%

Comprehensive introduction to biperiden's pharmacologic properties, clinical utility, safety profile, and enduring role within movement disorder care pathways

Biperiden is an anticholinergic agent with an established role in symptomatic management of movement disorders, notably Parkinsonian symptoms and drug-induced extrapyramidal reactions. Clinicians continue to rely on its pharmacologic profile to modulate muscarinic receptor-mediated pathways, thereby reducing tremor and rigidity in select patient populations. The compound's route-specific formulations and dose variations enable clinicians to match therapeutic intent with tolerability considerations, particularly in older adults who often present with polypharmacy and comorbidities.

Although newer therapeutics have expanded the armamentarium for movement disorder care, biperiden retains clinical relevance because of its targeted mechanism, rapid onset of symptomatic relief in many cases, and the availability of generic forms that can fit within constrained formularies. Regulatory expectations for anticholinergic agents emphasize safety monitoring, especially cognitive and cardiovascular effects in geriatric patients, necessitating clear prescribing guidance. Consequently, stakeholders from clinicians to procurement leaders must balance efficacy, safety, and access concerns when considering biperiden as part of therapeutic pathways.

Analysis of clinical, regulatory, and supply chain forces driving strategic and operational shifts across the biperiden therapeutic and commercial landscape

The therapeutic and commercial landscape for biperiden is experiencing several transformative shifts driven by evolving clinical guidelines, demographic pressures, and supply chain dynamics. Clinically, there is a growing emphasis on individualized therapy that accounts for age-related pharmacodynamics and the cumulative anticholinergic burden from polypharmacy. This trend favors more cautious prescribing and closer monitoring, which in turn impacts demand patterns across different formulations and care settings.

Concurrently, manufacturing and distribution channels are adapting to heightened regulatory scrutiny and to the need for resilient sourcing of active pharmaceutical ingredients. Technological advances in formulation and delivery, such as improved oral solid dosage uniformity and more stable parenteral preparations, are altering procurement choices for hospitals and clinics. In parallel, payer and policy developments are shaping formulary decisions and reimbursement pathways, creating pressure for cost-effective generic alternatives while sustaining the clinical need for branded innovations in specific clinical niches. Together, these forces are reshaping how stakeholders evaluate therapeutic fit, supply reliability, and long-term product stewardship for biperiden.

Assessment of how policy-driven tariff adjustments have altered supply chain economics, sourcing behavior, and continuity planning within the biperiden supply chain

The cumulative impact of tariff policy changes implemented in the United States during 2025 has introduced an additional layer of complexity for stakeholders involved in the procurement and distribution of pharmaceutical inputs and finished products. Increased duties on certain imported pharmaceutical components and packaging materials have raised input cost pressures for manufacturers that rely on globalized supply chains. These pressures are transmitted through contract manufacturers, wholesalers, and ultimately institutional purchasers, necessitating adjustments in sourcing strategies and inventory planning.

As firms respond, there is an observable pivot toward supplier diversification, nearshoring of key manufacturing steps where feasible, and renegotiation of long-term procurement contracts to share risk. Clinical stakeholders have noted potential short-term supply tightness for some parenteral formulations due to lead-time extensions and shifts in production priorities. At the same time, payers and procurement leaders have intensified focus on total cost of care, prompting more rigorous assessment of therapeutic alternatives and substitution practices. These dynamics underscore the need for proactive supply chain mapping and cross-functional contingency planning to preserve access and maintain continuity of care for patients reliant on biperiden therapies.

Segment-focused insights integrating formulation, type, indication, administration route, patient demographics, and end-user characteristics to inform clinical and commercial strategies

Insights derived from segmentation lenses reveal differentiated clinical and commercial dynamics that inform product positioning and stakeholder engagement. Based on formulation, the landscape divides into injectable and oral options, with oral preparations further evaluated at established dose levels of 2 mg and 4 mg; injectable formats remain critical for acute management in institutional settings while oral dosages enable titration and outpatient maintenance. Based on type, branded offerings compete with generic equivalents, where branded products often emphasize formulation or supply reliability while generics prioritize broad formulary acceptance and cost containment. Based on indication, product use primarily addresses extrapyramidal symptoms and Parkinson's disease, with each indication presenting distinct prescribing patterns, monitoring requirements, and patient outcome expectations.

Based on route of administration, oral versus parenteral pathways influence distribution decisions and caregiver training requirements, as oral routes support home-based care and parenteral routes are integral to inpatient clinical workflows. Based on patient age group, differences between adults and geriatric populations highlight divergent safety considerations, comorbidity management, and adherence challenges, with geriatric prescribing demanding heightened vigilance around anticholinergic burden. Based on end-user, clinics, home care settings, and hospitals each exert different procurement pressures and clinical expectations, from rapid-response inpatient protocols to long-term outpatient adherence support, informing tailored commercialization and support strategies for product manufacturers and distributors.

Regional analysis of regulatory, procurement, manufacturing, and clinical adoption dynamics shaping biperiden access across the Americas, EMEA, and Asia-Pacific

Regional dynamics shape demand drivers, regulatory interactions, and supply chain priorities for biperiden across broad global footprints. In the Americas, policy emphasis on formulary efficiency and cost containment guides payer negotiation strategies, while consolidated distribution networks facilitate rapid scale-up but are sensitive to tariff and trade policy shifts that affect imported inputs. In the Europe, Middle East & Africa region, heterogeneous regulatory frameworks and variable healthcare infrastructure create differentiated adoption pathways; some jurisdictions emphasize centralized procurement and strict pharmacovigilance, whereas others prioritize local manufacturing partnerships to ensure supply continuity. In the Asia-Pacific region, manufacturing capacity, active pharmaceutical ingredient sourcing, and a growing emphasis on geriatric care are key determinants of therapeutic prioritization, with regional production hubs playing a central role in global supply chains.

Across these regions, regulatory alignment, cross-border logistics, and regional reimbursement mechanisms shape long-term access strategies. Consequently, stakeholders should calibrate launch sequencing, regulatory submissions, and distribution partnerships in accordance with regional procurement norms, clinical practice patterns, and supply chain resilience considerations to ensure reliable availability and appropriate clinical utilization of biperiden.

Competitive and operational intelligence on manufacturers, contract partners, and service providers that determine product availability, formulation differentiation, and clinical support for biperiden

Competitive dynamics among manufacturers, contract developers, and specialty suppliers influence the availability, formulation innovation, and supply reliability for biperiden. Established generic manufacturers sustain broad availability through high-volume production and distribution networks, while specialty pharmaceutical firms may differentiate through formulation enhancements, stability improvements for parenteral presentations, or tailored packaging that enhances dosing accuracy. Contract development and manufacturing organizations are increasingly important as sponsors outsource production to manage capital intensity and regulatory compliance demands; robust quality systems and diversified supplier bases are therefore critical competitive advantages.

Commercial leadership is also influenced by firms that can integrate pharmacovigilance infrastructure and clinician support services, enabling safer use in geriatric populations and in complex polypharmacy contexts. Strategic partnerships between manufacturers and hospital systems or clinic networks can secure preferred procurement pathways and facilitate clinician education on appropriate prescribing. In short, organizational capabilities in reliable production, regulatory compliance, and clinician engagement will determine which companies are best positioned to meet evolving clinical needs and supply chain expectations for biperiden therapies.

Actionable strategic and operational recommendations for manufacturers, distributors, and healthcare stakeholders to protect access and optimize biperiden utilization

Industry leaders should adopt multi-dimensional strategies that preserve patient access while managing cost and regulatory risk. First, strengthening supply chain resilience by diversifying API sources and qualifying multiple contract manufacturing partners will reduce exposure to trade policy shocks and capacity bottlenecks. Second, investing in formulation robustness-improving stability for parenteral preparations and optimizing oral dosage uniformity at clinically relevant strengths-will address clinician concerns about reliability and adherence. Third, enhancing post-market safety monitoring and clinician education programs, particularly focused on anticholinergic burden in geriatric patients, will mitigate safety risks and support appropriate prescribing practices.

Moreover, commercial teams should pursue differentiated value propositions for branded products that emphasize supply continuity, clinician support, and formulation benefits, while working with payers and procurement entities to articulate total cost implications and patient outcomes. Finally, cross-functional contingency planning that aligns regulatory, manufacturing, and commercial functions will enable rapid response to policy changes and logistic disruptions. By implementing these recommendations, stakeholders can maintain therapeutic continuity for patients while navigating an increasingly complex operational environment.

Rigorous multi-method research approach combining literature synthesis, stakeholder interviews, and supply chain mapping to derive clinically grounded and operationally relevant insights

The research methodology underpinning this analysis combined systematic literature review, regulatory guidance synthesis, stakeholder interviews, and supply chain mapping to ensure a comprehensive evidence base. Secondary sources included peer-reviewed clinical literature, pharmacology references, and public regulatory documentation to establish clinical context and safety considerations. Primary research comprised structured interviews with clinicians, procurement specialists, and manufacturing experts to capture real-world prescribing patterns, procurement priorities, and operational constraints. These insights were triangulated to validate themes and reconcile divergent perspectives across care settings.

Supply chain analysis employed a component-by-component mapping of active ingredient sourcing, finished product manufacturing, and distribution nodes to identify vulnerability points and adaptation strategies. Throughout the research process, attention was given to methodological rigor, transparency of assumptions, and acknowledgement of data limitations, including variability across regional regulatory environments and the evolving nature of tariff policies. The resulting approach balances depth of clinical understanding with operational intelligence to support practical decision-making.

Concluding synthesis of clinical relevance, operational challenges, and strategic priorities to sustain access and safe use of biperiden across care settings

In closing, biperiden remains a clinically valuable option within the therapeutic landscape for movement disorders, particularly for selected cases of Parkinson's-related symptoms and drug-induced extrapyramidal reactions. The interaction of clinical preferences, regulatory expectations, demographic trends, and supply chain pressures is reshaping how stakeholders approach formulation choice, procurement, and patient safety management. Adapting to these dynamics requires coordinated actions across manufacturing, clinical practice, and procurement functions to ensure that therapeutic availability aligns with evolving standards of care.

Moving forward, organizations that proactively strengthen supply chain resilience, prioritize formulation and safety enhancements, and engage clinicians through targeted education will be best positioned to sustain access and deliver patient-centered outcomes. Continuous monitoring of policy developments, especially those affecting trade and procurement, will be essential for maintaining continuity of care and for making informed operational adjustments as external conditions evolve.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biperiden Market, by Formulation

  • 8.1. Injectable
  • 8.2. Oral
    • 8.2.1. 2 mg
    • 8.2.2. 4 mg

9. Biperiden Market, by Type

  • 9.1. Branded
  • 9.2. Generic

10. Biperiden Market, by Indication

  • 10.1. Extrapyramidal Symptoms
  • 10.2. Parkinson's Disease

11. Biperiden Market, by Route Of Administration

  • 11.1. Oral
  • 11.2. Parenteral

12. Biperiden Market, by Patient Age Group

  • 12.1. Adults
  • 12.2. Geriatric

13. Biperiden Market, by End-User

  • 13.1. Clinics
  • 13.2. Home Care
  • 13.3. Hospitals

14. Biperiden Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Biperiden Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Biperiden Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Biperiden Market

18. China Biperiden Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Apotex Inc.
  • 19.6. Aurobindo Pharma Limited
  • 19.7. Dr. Reddy's Laboratories Ltd.
  • 19.8. Glenmark Pharmaceuticals Limited
  • 19.9. Janssen-Cilag International NV
  • 19.10. Lupin Limited
  • 19.11. Sandoz International GmbH
  • 19.12. Sun Pharmaceutical Industries Ltd.
  • 19.13. Teva Pharmaceutical Industries Ltd.
  • 19.14. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIPERIDEN MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIPERIDEN MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BIPERIDEN MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BIPERIDEN MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BIPERIDEN MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIPERIDEN MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BIPERIDEN MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIPERIDEN MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BIPERIDEN MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BIPERIDEN MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES BIPERIDEN MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA BIPERIDEN MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BIPERIDEN MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BIPERIDEN MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIPERIDEN MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIPERIDEN MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIPERIDEN MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BIPERIDEN MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIPERIDEN MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIPERIDEN MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIPERIDEN MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BIPERIDEN MARKET SIZE, BY 2 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIPERIDEN MARKET SIZE, BY 2 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BIPERIDEN MARKET SIZE, BY 2 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIPERIDEN MARKET SIZE, BY 4 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BIPERIDEN MARKET SIZE, BY 4 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIPERIDEN MARKET SIZE, BY 4 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BIPERIDEN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIPERIDEN MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BIPERIDEN MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIPERIDEN MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BIPERIDEN MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIPERIDEN MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BIPERIDEN MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIPERIDEN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BIPERIDEN MARKET SIZE, BY EXTRAPYRAMIDAL SYMPTOMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIPERIDEN MARKET SIZE, BY EXTRAPYRAMIDAL SYMPTOMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BIPERIDEN MARKET SIZE, BY EXTRAPYRAMIDAL SYMPTOMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIPERIDEN MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BIPERIDEN MARKET SIZE, BY PARKINSON'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIPERIDEN MARKET SIZE, BY PARKINSON'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIPERIDEN MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BIPERIDEN MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIPERIDEN MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BIPERIDEN MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIPERIDEN MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BIPERIDEN MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BIPERIDEN MARKET SIZE, BY ADULTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIPERIDEN MARKET SIZE, BY ADULTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BIPERIDEN MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIPERIDEN MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BIPERIDEN MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIPERIDEN MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BIPERIDEN MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIPERIDEN MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BIPERIDEN MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIPERIDEN MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BIPERIDEN MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIPERIDEN MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BIPERIDEN MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIPERIDEN MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BIPERIDEN MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIPERIDEN MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BIPERIDEN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS BIPERIDEN MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS BIPERIDEN MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS BIPERIDEN MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS BIPERIDEN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS BIPERIDEN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS BIPERIDEN MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA BIPERIDEN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA BIPERIDEN MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA BIPERIDEN MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA BIPERIDEN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA BIPERIDEN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA BIPERIDEN MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA BIPERIDEN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA BIPERIDEN MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA BIPERIDEN MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA BIPERIDEN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA BIPERIDEN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA BIPERIDEN MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA BIPERIDEN MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA BIPERIDEN MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA BIPERIDEN MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA BIPERIDEN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA BIPERIDEN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA BIPERIDEN MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE BIPERIDEN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE BIPERIDEN MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE BIPERIDEN MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE BIPERIDEN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE BIPERIDEN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE BIPERIDEN MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST BIPERIDEN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST BIPERIDEN MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 97. MIDDLE EAST BIPERIDEN MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST BIPERIDEN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST BIPERIDEN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST BIPERIDEN MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA BIPERIDEN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA BIPERIDEN MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA BIPERIDEN MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA BIPERIDEN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA BIPERIDEN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA BIPERIDEN MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC BIPERIDEN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC BIPERIDEN MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC BIPERIDEN MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC BIPERIDEN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC BIPERIDEN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC BIPERIDEN MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL BIPERIDEN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN BIPERIDEN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. ASEAN BIPERIDEN MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 122. ASEAN BIPERIDEN MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN BIPERIDEN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN BIPERIDEN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN BIPERIDEN MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 128. GCC BIPERIDEN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GCC BIPERIDEN MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 130. GCC BIPERIDEN MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 131. GCC BIPERIDEN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. GCC BIPERIDEN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 133. GCC BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 134. GCC BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GCC BIPERIDEN MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPEAN UNION BIPERIDEN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION BIPERIDEN MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION BIPERIDEN MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION BIPERIDEN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION BIPERIDEN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPEAN UNION BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION BIPERIDEN MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS BIPERIDEN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS BIPERIDEN MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 146. BRICS BIPERIDEN MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS BIPERIDEN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. BRICS BIPERIDEN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 149. BRICS BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS BIPERIDEN MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 152. G7 BIPERIDEN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. G7 BIPERIDEN MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 154. G7 BIPERIDEN MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 155. G7 BIPERIDEN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. G7 BIPERIDEN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 157. G7 BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 158. G7 BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. G7 BIPERIDEN MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 160. NATO BIPERIDEN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. NATO BIPERIDEN MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 162. NATO BIPERIDEN MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 163. NATO BIPERIDEN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. NATO BIPERIDEN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 165. NATO BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 166. NATO BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. NATO BIPERIDEN MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL BIPERIDEN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES BIPERIDEN MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 170. UNITED STATES BIPERIDEN MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 171. UNITED STATES BIPERIDEN MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES BIPERIDEN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. UNITED STATES BIPERIDEN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 174. UNITED STATES BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED STATES BIPERIDEN MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 177. CHINA BIPERIDEN MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 178. CHINA BIPERIDEN MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 179. CHINA BIPERIDEN MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 180. CHINA BIPERIDEN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. CHINA BIPERIDEN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 182. CHINA BIPERIDEN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 183. CHINA BIPERIDEN MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 184. CHINA BIPERIDEN MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)